A judge in Washington, D.C., has issued a ruling requiring a man to cease smoking medical marijuana in his apartment because of complaints from a neighbor about the intrusive odor. Judge Ebony Scott determined that Josefa Ippolito-Shepherd had not proven her entitlement to damages but successfully argued that the smell constituted a private nuisance.

Consequently, Scott ordered Thomas Cackett, who is licensed to purchase marijuana but lacks the authorization to disrupt others’ enjoyment of their property, to discontinue his smoking habit. Additionally, Cackett is prohibited from smoking within a 25-foot radius of Ippolito-Shepherd’s residence.

This groundbreaking decision is expected to set a precedent that may result in further legal action. Ippolito-Shepherd expressed her belief that the ruling is a victory for individuals such as her who have lodged complaints about the smell of marijuana, which has been permitted in various forms in most states.

During the January trial, the 76-year-old asserted that she has experienced health issues, including sleep difficulties, since detecting the scent of marijuana in her Cleveland Park home. Ippolito-Shepherd accused Angella Farserotu, the owner of the adjacent property, of enabling Cackett, a tenant in a ground-level accessory apartment, to smoke without facing consequences. Farserotu and Cackett countered by stating that they bear no legal responsibility for Ippolito-Shepherd’s ailments.

This ruling arrives at a time when concerns surrounding the odor of marijuana have emerged alongside the flourishing cannabis industry. Operating within a legal gray area where marijuana remains illegal at the federal level but is sanctioned by individual states, users, sellers and growers have approached this new frontier cautiously. The legal ramifications associated with the smell have now become an additional concern.

During the court proceedings, Cackett testified that smoking medical marijuana alleviates his pain and aids his sleep following physically demanding shifts as a restaurant manager. He refuted the plaintiff’s claims of smoking continuously throughout the day and night, stating that he typically consumes eight to twelve puffs at night after work, usually outdoors if weather conditions permit.

According to public health experts, passive marijuana smoke contains some of the same cancer-causing toxins found in passive tobacco smoke. However, the federal classification of marijuana as a Schedule I drug has hindered long-term studies on its effects and passive smoking.

Advocates for marijuana legalization have expressed concerns that restrictions on smoking locations could limit individuals access to the drug for medical or recreational purposes. Due to marijuana’s federal legal status, federal disability protections do not extend to medical cannabis patients. As complaints related to the now-legal drug’s odor increase, certain cities in California have contemplated banning smoking in multiunit housing. While alternative methods of marijuana consumption exist, such as ingestion or vaping, smoking remains the most prevalent approach.

Some proponents of legalized cannabis sympathize with the notion that marijuana smoke can be bothersome and generally agree that responsible consumption entails being considerate of neighbors and surroundings. They argue that expanding and regulating designated public spaces for cannabis use, similar to the regulations applied to tobacco, would offer the best solution.

This lawsuit illustrates some of the challenges that people who use cannabis for medical reasons face, and one may be compelled to think that the efforts of enterprises such as IGC Pharma Inc. (NYSE American: IGC) to come up with pharmaceutical-grade formulations from THC could help patients wishing to benefit from the therapeutic potential of marijuana without facing the wrath of neighbors who aren’t comfortable with the smell of marijuana smoke.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The Louisiana Senate has approved a measure to expunge certain cannabis-related offenses from people’s records and sent the bill to the governor. The new bill will provide a streamlined pipeline that allows people with first-time convictions for cannabis possession to expunge their records.

Most pundits agree that the war on drugs was a failure that led to the incarceration of millions of Americans for relatively minor offenses, and decimated local communities while allowing the criminal institutions behind the illicit drug trade to flourish.

Authorities were especially hard on people of color during the failed drug war and studies now show that Black people were significantly more likely to be arrested and sentenced harshly for cannabis use despite similar use rates with White people.

The majority of states with legal cannabis programs now have expungement laws that allow people with prior cannabis convictions to petition for them to be expunged from their records.

Representative Delisha Boyd introduced the expungement bill in May 2023, and it cleared the House before passing through a key Senate committee. Senate lawmakers then chose to pass the bill via a 32–7 vote before sending it to Governor John Bel Edwards.

If Governor Edwards signs the bill into law, people who were convicted for possessing up to 14 grams of marijuana as their first offense will be able to file a petition at the court to have their records expunged three months after receiving the conviction. Given that current Louisiana law requires that residents wait for five years before they can petition the court to expunge certain records, this bill will significantly expedite the process.

A House committee amended the original version of the cannabis expungement bill to state that only possession cases involving up to 14 grams of cannabis were eligible for expedited expungement.  Furthermore, the committee amended the bill to remove provisions eliminating court-processing fees for eligible Louisiana residents and set a $300 cap on the court fees.

The legislation’s language states that the clerk should send equal shares of court processing fees for first-time cannabis conviction expungements to the district attorney and the sheriff.

The move was met with praise by reform activists in the state. Marijuana Policy Project (MPP) legislative manager Kevin Caldwell said in an interview that the organization is excited to see further advances in cannabis policy in the historically conservative state. He explained that Louisiana has one of the costliest and most complicated expungement processes in the country, with most people who seek expungement being forced to pay at least $550 per incident.

This new expungement bill could allow “tens of thousands of Louisianans” to finally clear their records and live their lives without being held back by a criminal record.

While Louisiana is taking steps to expunge the criminal records of individuals who were convicted for certain marijuana-related crimes, several companies such as IGC Pharma Inc. (NYSE American: IGC) want to make FDA-approved cannabis medicines available to the public to help them in managing or treating some ailments, such as chronic pain. Such medicines wouldn’t come with any risk of facing arrest and incarceration since the formulations would have the required regulatory approvals and patients can get them through their doctors.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The convergence of cannabinoids and psilocybin in a unified formulation to address physical and psychological well-being has moved closer to realization as highlighted in a patent filed by a prominent cannabinoid laboratory called CaaMTech. Situated in Issaquah, Washington, just under 20 miles southeast of Seattle, CaaMTech is conducting an analysis of the mutual interactions between these two compounds and the specific outcomes they can yield in terms of physical and mental health.

Presently, the company’s refined psilocybin-cannabinoid formulation is still in the early stages of development. This patent progress comes at a time when the availability of genetic information on marijuana and psilocybin is increasing, which presents opportunities to explore novel ways in which these substances can collaborate, potentially resulting in the creation of innovative commercial offerings.

For example, the combination of marijuana and psilocybin has demonstrated tumor reduction in the case report of a 49-year-old woman with breast cancer. This discovery has prompted researchers to conclude that mounting empirical and anecdotal evidence supports the therapeutic potential of cannabinoids as well as psychedelics in diminishing tumor growth while also providing relief from pain and psychological distress associated with cancer and chemo.

Researchers now envision a comprehensive solution to address extreme mental health disorders and inflammation by harnessing the beneficial properties of both substances. One potential approach involves incorporating psilocybin with a minor cannabinoid such as cannabichromene (CBC), which is abundantly present in cannabis plants. This amalgamation could potentially result in a one-time treatment option.

Daniel McQueen, executive director of the Boulder, Colorado-based Center for Medicinal Mindfulness and author of a book titled “Psychedelic Cannabis,” has been facilitating marijuana-assisted psychedelic therapy at the organization. This therapy involves overseeing individual psychedelic cannabis and ketamine experiences alongside guided meditation, personal coaching, educational classes, as well as community support.

McQueen agrees that the creation of a psilocybin-marijuana pill or combination compound is entirely feasible. Nevertheless, there are significant obstacles to overcome in developing such a compound. Cannabinoids and psychedelics interact with distinct receptors in the brain. THC, a cannabinoid, predominantly binds to CB1 receptors, while CBC primarily binds to CB2 receptors. On the other hand, psilocybin, a psychedelic, primarily binds to 5-HT2A serotonin receptors.

However, research has indicated that CBD, one of the abundant cannabinoids, interacts with serotonin’s receptors, and when serotonin is coupled with a CB2 cannabinoid receptor, this combination can produce effects that none of the receptors can achieve independently. A study conducted by Spanish scientists in 2022 focusing on ischemia in newborn piglets revealed that CBD activates serotonin receptors, leading to neuroprotective effects.

Researchers continue to diligently seek improved solutions to address mental health concerns, regardless of the substances involved.

Other research teams, such as the team at IGC Pharma Inc. (NYSE American: IGC), are focusing on developing therapeutics from THC and other cannabinoids for use in the mainstream healthcare system.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

A recent study funded by the federal government highlights the challenges associated with developing a cannabis breathalyzer. The research, conducted by National Institute of Standards and Technology (NIST) and Colorado Boulder University, demonstrates that determining recent marijuana use based on THC levels in breath is highly unreliable due to inconsistencies.

The study, published in the “Breath Research” Journal, involved 18 participants from Colorado who consumed retail marijuana with approximately 25% THC. Breath and blood samples were taken 15 minutes before and one hour after smoking marijuana, using a well-equipped white van conveniently parked outside their homes. The analysis was conducted in a laboratory setting, as NIST clarified that it is not currently working on a breathalyzer device. Instead, the agency concentrated on learning more about how to precisely measure THC and other related substances in a breath sample.

Only 8 of the 14 individuals who supplied breath samples before and after using marijuana showed the anticipated increase in THC levels. The remaining findings lacked clarity, with three after-use breath samples exhibiting no detectable THC, and the others exhibiting amounts that were comparable to or lower than the baseline.

In contrast, the study found that the level of THC in the blood, specifically measured through plasma, proved to be a more accurate indicator of recent marijuana use. Even though THC levels in blood demonstrated compliance with the study procedure and showed a considerable increase right after usage, THC levels in breath after an hour did not always surpass the baseline.

Tara Lovestead, the supervisory chemical engineer at NIST and coauthor of the report, expressed surprise at the similar range of THC levels in breath samples taken before and after marijuana use.

While the study’s small scale limits the statistical significance of the results, NIST and the authors emphasized the need for more research.

As cannabis legalization progresses in more states, entrepreneurs and scientists are striving to create THC field sobriety tests, such as breathalyzers. However, despite efforts from companies such as Hound Labs in Oakland, California, which anticipated deploying its device to regulators and law enforcement in 2016, widespread adoption of any marijuana field sobriety test has not yet been achieved.

The recent study received funding from a grant provided by the DOJ’s National Institute of Justice. The study team has also received an extra $1.5 million to carry out and expand the study. To provide more statistically meaningful results, the following phase will include 40 or more people and more breath samples.

The marijuana industry is still in flux, and much could change at the state and federal level regarding the way in which this substance is regulated. This is because policy often evolves in response to the emerging scientific data about something, and marijuana policy is no different. As society changes its perception towards marijuana, we are seeing many companies such as IGC Pharma Inc. (NYSE American: IGC) seeking to tap the medicinal qualities of cannabis by developing formulations for chronic pain and other indications from compounds extracted from the marijuana plant. These drugs could broaden the options that patients have in the coming years.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The federal regulatory agency overseeing the firearms industry, the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF), has issued a cautionary notice emphasizing that residents of Minnesota who partake in marijuana consumption cannot legally possess firearms, despite the state’s recent legalization of recreational use.

While marijuana has been legalized for adults in 23 states and many others have implemented medical cannabis programs, the substance remains classified as a schedule I controlled substance under federal law, along with heroin and LSD. According to the St. Paul ATF office, individuals who engage in marijuana smoking or consume cannabis edibles are still regarded as “unlawful users” of a controlled substance in the eyes of the federal government. Consequently, they are barred from owning, transporting, receiving or possessing ammunition and firearms.

Jeff Reed, the acting special agent in charge of the St. Paul field division, urged gun owners to exercise caution, emphasizing that the combination of marijuana and firearms or ammunition remains a federal offense until marijuana is federally legalized.

Rob Doar, an advocate for second amendment rights and vice president of the Minnesota Gun Owners Caucus, finds the ATF’s advisory troubling. He has long been aware of the conflicting state and federal cannabis laws, regardless of whether it is used for medical or recreational purposes. Doar advises firearm owners to be mindful of the risks involved, despite the new law in Minnesota preventing sheriffs from denying carry permits based solely on participation in the medical cannabis program or adult marijuana use.

Doar actively advocated for the inclusion of this provision. “If ATF agents did not intend to enforce it, they might have let it slide,” he said, “creating a sort of unofficial acceptance that although it is illegal, similar to other federal cannabis regulations, it would not be enforced. The fact that they issued a notice raises concerns.”

Jason Tarasek, a cannabis attorney representing Vicente LLP, acknowledges that the federal government has generally turned a blind eye to states that have legalized marijuana, allowing them to operate without interference. However, he recognizes the predicament faced by gun owners. “We are currently navigating an intricate dance with the federal government,” he remarked.

Both Tarasek and Doar hope for clear guidance from Washington, whether through legislative measures or executive actions taken by the Biden administration. Tarasek believes that unambiguous direction from the federal government would provide reassurance to individuals in legal cannabis markets, alleviating concerns about potential federal repercussions.

However, Tarasek does not anticipate federal legalization in the near future. He points out that a decade ago, during the Obama administration, the Department of Justice issued guidelines indicating that it would not interfere with states that legalized marijuana as long as it did not hinder federal law enforcement priorities. Unfortunately, these guidelines were rescinded by then-U.S. Attorney General Jeff Sessions during President Donald Trump’s tenure.

The dilemmas that users of medical marijuana face in states where such programs exist justify the attempts by enterprises such as IGC Pharma Inc. (NYSE American: IGC) to formulate medicines that pass FDA scrutiny. Such formulations would address the medical needs of patients without posing any risk of adverse legal repercussions.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.